Satralizumab is a subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The DrugMonitor™ Anti-Satralizumab Antibody (VS-1224-YC1063) is an anti-drug antibody (ADA) against Satralizumab. This drug-based antibody is raised in mice immunized with the Satralizumab. The anti-Satralizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Satralizumab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-IL6R ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-032ML)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL6R. It is a human monoclonal antibody that can be potentially used in the treatment of Neuromyelitis optica (NMO).
There are currently no Customer reviews or questions for VS-1224-YC1063. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.